Rigel Pharmaceuticals, Inc. /
Blueprint Medicines Corporation
Rigel to purchase U.S. pralsetinib rights from Blueprint Medicines Corporation
What happened
Rigel Pharmaceuticals, Inc. agreed to purchase certain U.S. rights related to pralsetinib from Blueprint Medicines Corporation. The agreement includes a $15.0 million purchase price, along with potential future commercial and regulatory milestone payments.
The assets include intellectual property, clinical regulatory and commercial data, and records related to pralsetinib, a RET inhibitor used to treat certain lung and thyroid cancers.
The source
Everything on this page comes from the source below.
Rigel to purchase U.S. pralsetinib rights from Blueprint Medicines Corporation
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly